How should cirrhosis caused by Wilson disease be managed?

Management of Wilson Disease Cirrhosis

Patients with compensated Wilson disease cirrhosis should receive lifelong chelation therapy with D-penicillamine or trientine, while those with decompensated cirrhosis require combination therapy with a chelator plus zinc, and patients with acute liver failure need urgent liver transplantation. 1

Initial Assessment and Diagnosis Confirmation

When cirrhosis is identified in a Wilson disease patient, confirm the diagnosis with:

• Serum ceruloplasmin, 24-hour urinary copper excretion, liver biochemistries, complete blood count, and INR 1
• Slit-lamp examination for Kayser-Fleischer rings 2
• Liver biopsy for hepatic copper quantification if diagnosis remains uncertain 2
• Screen all first-degree relatives, as this is mandatory 2

Cirrhosis at diagnosis is the strongest predictor of death (odds ratio 6.8) and need for liver transplantation (odds ratio 0.07), with only 84% of cirrhotic patients surviving 20 years compared to 92% overall. 3

Treatment Strategy Based on Disease Severity

Compensated Cirrhosis (Stable Liver Function)

Initiate chelation therapy immediately with either D-penicillamine or trientine as first-line treatment. 2, 1, 4

D-Penicillamine dosing:

• Initial dose: 750-1500 mg/day in divided doses 1
• Maintenance dose: After 2-6 months of stabilization, reduce to maintenance levels 2
• Must supplement with pyridoxine 25-50 mg daily 1
• Take 1 hour before or 2 hours after meals 1

Trientine dosing (preferred if penicillamine intolerance):

• Initial dose: 750-1500 mg/day in 2-3 divided doses 1
• Maintenance: 750-1000 mg/day 1
• Children: 20 mg/kg/day rounded to nearest 250 mg 1
• Take 1 hour before or 2 hours after meals 1

After 1-5 years of stable chelation therapy, patients may transition to zinc monotherapy for maintenance if they achieve:

• Normal aminotransferases and hepatic synthetic function 1
• Normal non-ceruloplasmin bound copper 1
• 24-hour urinary copper 200-500 µg/day on treatment 1

Decompensated Cirrhosis (Hypoalbuminemia, Coagulopathy, Ascites)

Use intensive combination therapy with both a chelator and zinc, administered separately throughout the day. 1

Specific regimen:

• Zinc 50 mg elemental (25 mg in children) as doses 1 and 3 1
• Trientine 500 mg (or 10 mg/kg in children) as doses 2 and 4 1
• Maintain 5-6 hours between chelator and zinc to prevent binding 1
• This is an intensive induction regimen 1

After 3-6 months of response, transition to monotherapy with either full-dose zinc or full-dose chelator. 1

Refer immediately to a transplant center, as some patients will fail medical therapy and require transplantation. 1

One case report demonstrated resolution of decompensated cirrhosis with zinc monotherapy alone, though this remains investigational and requires further validation. 5

Acute Liver Failure

Liver transplantation is the only effective treatment and is life-saving. 1, 2, 1, 6

Use prognostic scoring to identify transplant candidates:

• Nazer score ≥7 (bilirubin, AST, PT prolongation) predicts non-survival without transplant 1, 2, 1
• List immediately for urgent transplantation 1

Bridge to transplant with:

• Plasmapheresis and hemofiltration to protect kidneys from copper-mediated tubular damage 1, 2, 1
• Albumin dialysis or MARS ultrafiltration to stabilize patients (delays but does not eliminate need for transplant) 1, 2, 1

Transplant outcomes:

• 1-year survival: 79-87% 1, 4
• Better outcomes with chronic decompensated disease (90%) than acute liver failure (73%) 4
• Corrects the underlying metabolic defect 1
• Living donor transplantation is feasible, even from heterozygous family members 2, 1, 4

Monitoring During Treatment

Monitor at minimum twice yearly, more frequently during initial treatment or if symptoms worsen. 2, 1

Laboratory monitoring:

• Liver biochemistries, albumin, bilirubin, INR 2, 1
• Serum ceruloplasmin and copper 2, 1
• Non-ceruloplasmin bound copper (best guide to treatment efficacy) 1
• 24-hour urinary copper excretion while on medication 2, 1

Target urinary copper values:

• On chelation therapy: 200-500 µg/day (3-8 µmol/day) 1
• On zinc therapy: ≤75 µg/day (1.2 µmol/day) 1
• Values <200 µg/day on chelation suggest either non-adherence (with elevated non-ceruloplasmin copper) or overtreatment (with very low non-ceruloplasmin copper) 1

Clinical monitoring:

• Physical examination for liver disease progression, neurological symptoms 1
• Repeat slit-lamp examination if non-compliance suspected 1
• Screen for psychiatric symptoms, especially depression 1

Cirrhosis-Specific Complications Management

Portal hypertension screening and management:

• Screen for esophageal varices routinely 7
• Primary/secondary prophylaxis with non-selective beta-blockers or variceal ligation 7

Ascites management:

• Diuretics as first-line treatment 7
• Paracentesis to diagnose spontaneous bacterial peritonitis, treat with antibiotics 7

Hepatic encephalopathy:

• Treat with laxatives and non-resorbable antibiotics 7
• Ensure regular defecation as prophylaxis 7

Infection prevention:

• Cirrhotic Wilson disease patients are highly susceptible to bacterial infections and sepsis 7
• Monitor closely for any infectious complications 7

Critical Management Principles

Treatment must be lifelong and never discontinued. 2, 1, 2, 1 Failure to comply leads to recurrent symptoms, liver failure requiring transplantation, and death. 2

Avoid hepatotoxic substances:

• Alcohol, hepatotoxic drugs 7
• Copper-rich foods (shellfish, nuts, chocolate, mushrooms, organ meats) especially in first year 1
• Copper cookware and containers 1
• Well water or water from copper pipes (flush stagnant water before use) 1

Pregnancy management:

• Continue treatment throughout pregnancy (discontinuation causes fulminant hepatic failure) 2, 1
• Reduce chelator dose by 25-50% in third trimester to promote wound healing if cesarean section needed 2, 1
• Maintain zinc dosage without change 2, 1
• Monitor frequently during pregnancy 1

Common Pitfalls

The most critical error is discontinuing treatment, which leads to intractable hepatic decompensation. 1 Early diagnosis at a precirrhotic stage significantly improves survival and reduces transplant need. 3 Chelating agents are recommended over zinc for significant liver disease, though zinc has shown promise even in severe cases. 4, 5 The 2025 EASL guidelines emphasize that only chelators should be used for significant liver disease. 6